With a purchase price of commercial rights for Zyprexa significantly above €1bn, this is the largest transaction in Cheplapharm's history.
The Administrative Council for Economic Defense of Brazil (CADE) has approved, without restrictions, the acquisition, by Cheplapharm, of Eli Lilly's assets for marketing and other purposes for the Zyprexa product. The drug is indicated for the treatment of schizophrenia and bipolar disorders.
The transaction includes product registrations and intellectual property, while it does not include any transfer of manufacturing facilities or employees.
As a leading acquirer of originator brands from big pharma companies, Cheplapharm has built up a strong and diversified portfolio of well-established medicines over the last 20 years.
Cheplapharm CEO Edeltraud Lafer said the acquisition of the commercial rights for Zyprexa strengthens the company's portfolio in the therapeutic area of the central nervous system and “opens completely new opportunities for the future.”
“This acquisition demonstrates our ability to manage increasingly bigger deals, while our deep and long-standing experience makes me quite confident that we will be able to ensure an efficient and seamless integration as well,”
Lafer said.
Cheplapharm is a fast-growing pharmaceutical company, headquartered in Greifswald, Germany, offering branded and niche products worldwide. The family-owned company specializes in selected active substances and indications.
Eli Lilly & Co. is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, USA. The company engages in the discovery, development, manufacture, marketing and sale of pharmaceutical products worldwide. Eli Lilly products are sold in approximately 120 countries.
Sources: Gov.br, Cheplapharm
